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Malignant cells are known to have increased glucose uptake
and accelerated glucose metabolism. Using liquid chromato-
graphy and mass spectrometry, we found that treatment of
acute lymphoblastic leukemia (ALL) cells with the glucocorti-
coid (GC) dexamethasone (Dex) resulted in profound inhibition
of glycolysis. We thus demonstrate that Dex reduced glucose
consumption, glucose utilization and glucose uptake by
leukemic cells. Furthermore, Dex treatment decreased the
levels of the plasma membrane-associated glucose transporter
GLUT1, thus revealing the mechanism for the inhibition of
glucose uptake. Inhibition of glucose uptake correlated with
induction of cell death in ALL cell lines and in leukemic blasts
from ALL patients cultured ex vivo. Addition of di-methyl
succinate could partially overcome cell death induced by Dex in
RS4;11 cells, thereby further supporting the notion that
inhibition of glycolysis contributes to the induction of apopto-
sis. Finally, Dex killed RS4;11 cells signiﬁcantly more efﬁciently
when cultured in lower glucose concentrations suggesting that
modulation of glucose levels might inﬂuence the effectiveness
of GC treatment in ALL. In summary, our data show that GC
treatment blocks glucose uptake by leukemic cells leading to
inhibition of glycolysis and that these effects play an important
role in the induction of cell death by these drugs.
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Introduction
Normal and tumor cells differ markedly in their energy
metabolism. When glucose, a primary source of energy, is
metabolized in normal cells in the presence of oxygen, the
process results in the complete oxidation of glucose and
involves cytoplasmic glycolysis and the mitochondrial citric
acid cycle and oxidative phosphorylation (OxPhos). In contrast,
tumor cells rely mostly on glycolysis, that is, conversion of
glucose into pyruvate and further into lactate, rather than on
mitochondrial OxPhos, even in the presence of adequate
oxygen. This phenomenon is referred as to the Warburg effect.
1
This pathway is not as efﬁcient as OxPhos in producing energy.
Therefore, to meet their high-energy demands, tumor cells
dramatically increase the rate of glycolysis. This is primarily
achieved by increased glucose uptake and expression of glucose
transporters, GLUTs, at the cell membrane.
2 The increased
dependence of cancer cells on glycolysis for energy production
is now generally regarded as a novel pathway for targeting in
cancer treatment.
Acute lymphoblastic leukemia (ALL) is the most common
childhood malignancy manifested by the expansion of immature
B or T cells. It has been shown that pre-B-ALL cells acquire an
altered glucose metabolism, higher expression of the glucose
transporter 1, GLUT1, and a particular sensitivity to the
glycolysis inhibitor 2-deoxy-D-glucose, 2-DG.
3 Glucocorticoids
(GCs) have been used as important therapeutic agents in the
treatment of ALL and other lymphoid malignancies for more
than 50 years.
4,5 In vivo and ex vivo GC sensitivity is a major
prognostic factor in childhood ALL
6,7 and treatment failure is
related to the resistance to GCs. It was demonstrated that GC
resistance in precursor-B-ALL is associated with increased
expression of genes involved in glucose metabolism
8 and that
an increased glycolytic rate in ALL cells is directly related to GC
resistance.
9 Importantly, this resistance could be reversed by
drugs that inhibit glycolysis, thus suggesting that targeting the
glycolytic pathway may be a valuable strategy to modulate GC
resistance.
9
The effect of GCs on lymphoid cells is dramatic and includes
G1-phase cell-cycle arrest and apoptosis. Induction of apoptosis
has been proposed to be the major effector mechanism for the
beneﬁcial effects of GC treatment in lymphoid malignancies.
10
We have also shown that dexamethasone (Dex)-induced
activation of the apoptotic response was associated with the
sensitivity to the drug in primary ALL samples, and that this
ex vivo Dex sensitivity correlated with an early response
to polychemotherapy.
11
Endogenous GCs are essential for the maintenance of blood
glucose levels. We therefore asked whether a part of the
therapeutic effect of GCs in ALL is mediated by affecting glucose
metabolism in the leukemic cells. Here, we show for the ﬁrst
time that the GC Dex profoundly affects the leukemic-cell
energy metabolism by inhibiting glucose utilization and uptake,
and downregulating GLUT1 expression in ALL cell lines.
Moreover, Dex-mediated inhibition of (2-18F) 2-ﬂuoro-2-
deoxy-D-glucose (FDG) uptake correlated with the ex vivo
sensitivity to the drug in primary leukemic blasts from pediatric
ALL patients, strongly suggesting that Dex-mediated cell killing
occurs through inhibition of glucose metabolism.
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Cell lines, culture conditions and treatment
Two pre-B ALL cell lines, RS4;11 (ATCC, no. CRL-1873, USA),
and SupB15 (DSMZFno. ACC 389, Germany), the T-ALL cell
line CCRF-CEM and the ALL cell line Reh-6 (F Albertioni,
Karolinska Institutet, Stockholm, Sweden) were used in this
study. The cells were cultured in RPMI 1640 medium (Sigma-
Aldrich Sweden AB, Stockholm, Sweden) (containing 25mM
Hepes for the RS4 and SupB15 cell lines), supplemented with
10% (v/v) heat-inactivated fetal calf serum, 2mML -glutamine,
50mg/ml streptomycin and penicillin (Invitrogen AB, Lidingo ¨,
Sweden) and maintained in a humidiﬁed incubator in 5% CO2
at 371C. Cells were treated with indicated doses of Dex (Oy
Organon AB, Helsinki, Finland), for the indicated times.
Glucose-free RPMI 1640 medium (Invitrogen) supplemented
with 1g/l and 0.5g/l of glucose was used in some experiments.
Liquid chromatography–mass spectrometry
Cold methanol (200ml) was added to frozen RS4;11 cells in
Eppendorf tubes together with a few mg of 0.25–0.5-mm glass
beads (Retsch GmbH, Haan, Germany) and an internal standard,
2H5-Phenylalanine (Cambridge Isotope Laboratories, Inc.,
Andover, MA, USA). The tubes were placed in a bead mill
(Retsch 301MM) and shaken at 30Hz for 30s. Samples were
subsequently spun at 16000RPM for 5min and the supernatant
was collected and evaporated to dryness in a Speedvac, and stored
at  801C until further analysis. For liquid chromatography–mass
spectrometry analysis, Agilent binary pump 1200 was coupled to
an Agilent 6410 triple quadrupole mass spectrometer, which was
operated in electrospray (ESI)-negative ionization mode. For
separation, we used hydrophilic interaction chromatography
(ZIC-HILIC, 2.1mm 100mm, Merck SeQuant AB, Umea ˚,
Sweden). Mobile phase (A) consisted of H2O, 25mM ammonium
acetate and (B) of 95:5 acetonitrile: H2O, 25mM ammonium
acetate. Chromatographic gradient proﬁle was as follows (150ml/
min): 0–1min 90% (B), 1–30min, linear gradient 90% (B) to 90%
(A), 30–40min 90% (A), 40–41min 90% (A) to 90% (B), 41–
60min re-equilibration at 90% (B). Before analysis, the samples
were re-suspended in 100ml 90:10 acetonitrile:H2O and 10ml
sample was injected on to the column for each analysis. Synthetic
standards of all analytes were obtained from Sigma Aldrich
(St Louis, MO, USA) and used for identiﬁcation of optimal multiple-
reaction monitoring transition and analyte retention time. The
selected multiple-reaction monitoring transitions were (with m/z
values inside the brackets): glyceraldehyde-3-phosphate (169-79),
phosphoenolpyruvate (167-79), lactate (89-43), NAD
þ (662-540),
NADP
þ (742-620), citrate (191-111) and malate (133-71). The ESI
potential was set to  4000V. The area representing the speciﬁc
analytes in each multiple-reaction monitoring chromatogram was
normalized to that of the internal standard (
2H5-Phenylalanine).
Patients and culture of primary cells
The study included leukemic cells from 19 patients diagnosed
with precursor-B ALL according to the World Health Organiza-
tion classiﬁcation.
12 Bone marrow (in 17 cases) or peripheral
blood (in two cases) were obtained on the day of diagnosis and
contained more than 80% leukemic blasts as established during
routine diagnostic procedure using the multiparameter ﬂuores-
cence-activated cell sorting analysis as described before.
13 All
patients or their parents were informed of the investigative
nature of this study, and informed consent was obtained from
each patient/parent in accordance with the ethical committee
requirements (Stockholm, Sweden).
Mononuclear cells were isolated from bone marrow or from
peripheral blood by centrifugation on a Ficoll/Hypaque
(Lymphoprep, Oslo, Norway) gradient and cryo-preserved in
liquid nitrogen. Leukemic cells were cultured ex vivo at a cell
concentration of 1 10
6/ml in RPMI 1640 culture medium as for
the cell lines (see above).
Inhibitors and antibodies
The GC-receptor (GR) antagonist RU38486 (RU486) was used at
100nM. Dimethyl succinate (Sigma-Aldrich) was used at
7.7mM as an extra energy source. The antibodies against
GLUT1 immunostainings were from R&D Systems Europe Ltd
(Abingdon, UK), and against GLUT1 and Na
þK
þ-ATPase
WesternsFfrom Abcam plc (Cambridge, UK); the allophyco-
cyanin-conjugated (APC) goat anti-mouse Ig was from
Pharmingen (Becton Dickinson, Stockholm, Sweden) and
ﬂuorescein isothiocyanate-conjugated swine anti-rabbit from
DakoCytomation (Glostrup, Denmark). Isotype-matched control
antibodies used were from DakoCytomation.
Assessment of apoptosis by immunostainings and ﬂow
cytometry
Apoptosis was assessed as redistribution of plasma membrane
phosphatidyl serine and changes in mitochondrial membrane
potential, DCm. Annexin V FLUOS (Roche Diagnostics Gmbh,
Mannheim, Germany) and tetramethylrhodamine ethyl ester
perchlorate (TMRE, Molecular Probes, Invitrogen AB) or annexin
V and propidium iodide (PI) double stainings were performed as
previously described.
14,15 The staining for GLUT1 was per-
formed according to the manufacturer’s instructions. At least
10000 events were acquired on a LSR II ﬂow cytometer (Becton
Dickinson) equipped with a 355nm UV laser or a ﬂuorescence-
activated cell sorting calibur ﬂow cytometer (Becton Dickinson).
Data were analyzed using the FlowJo (Tree Star, Inc., Olten,
Switzerland) and Cell Quest software (Becton Dickinson),
respectively.
Glucose consumption
Glucose consumption from the cell culture medium was
measured using the Amplex Red Glucose kit (Invitrogen,
Molecular Probes). Cells were set up at 200000 or 400000/ml
in triplicates and treated next day for 16 or 24h with 100nM
(RS4;11, SupB15, Reh cells) or 1uM (CEM cells) of Dex or 2mM
2DG. Supernatant samples were frozen from all time points
including 0h (at set up) that served as the base value. The
samples were diluted 400 or 1000-fold and the assay was
performed according to the manufacturer’s instructions. The
absorbance was measured at 560nm using a VERSAmax tunable
microplate reader. The values were calculated according to the
standard curve and then subtracted from the base line to obtain
values of glucose consumption from the growth culture medium
by the cells.
Glucose utilization and glucose uptake
Ttritium-labeled glucose and 2-DG were purchased from Sigma-
Aldrich Sweden AB. The material was puriﬁed from free tritium
by addition of water followed by freeze-drying twice. The
glucose was then kept frozen at  201C until use. Glucose
utilization was measured as previously described with minor
changes.
16 Brieﬂy, 50000 of the control or Dex pre-treated cells
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16.7mM (high) glucose and 1mCi [5-
3H] glucose in 100mlo f
Krebs bicarbonate buffer, pH 7.4. Each vial with its content was
placed in a scintillation bottle containing 500ml water, sealed
and gassed with O2/CO2 (19:1 by volume) for 3min. After a
90-min incubation at 371C, 100ml 0.1 M HCl was injected into
the vial to stop the reaction. The bottle and vial was left at room
temperature overnight to let the water in the bottle absorb the
3[H] water produced during glucose metabolism. The next day,
the vial with its acidiﬁed content was removed, and 10ml
scintillation ﬂuid (Ultima Gold; Packard, Perkin Elmer,
Upplands Va ¨sby, Sweden) was added to the bottle. The samples
were then assayed for radioactivity in a liquid scintillation
spectrophotometer (Tri-Carb 1900 TR liquid scintillation
analyzer; Packard). Parallel incubations were performed without
cells and with a known concentration of
3[H] water. Glucose
uptake was performed as described previously with minor
changes.
17 In short, cells were pre-treated with 100nM Dexa or
left untreated for indicated times. A total of 10
6 cells were
starved in phosphate-buffered saline at room temperature for
30min and incubated at 371C for 10min in phosphate-buffered
saline containing 5mM 2-[
3H]-2-DG. Scintillation ﬂuid (10ml)
was added and the samples were then assayed for [
3H] glucose
content in a liquid scintillation spectrophotometer. Average and
standard deviation of triplicates were calculated.
18F-2-DG uptake
Aliquots of [
18F] FDG produced for daily clinical PET studies at
the Karolinska Hospital were used in the experiments. Radio-
tracer synthesis was performed using a microlab (GE Healthcare,
Solna, Sweden) synthesis module, and all tests for radiochemical
identity and purity have been approved before release. Cells
were grown in a complete medium for 24h and then treated
with Dex for 6–16h in triplicate. The medium was changed to
glucose free and 10mCi of FDG was added to each sample and
incubated for 1h in 5% CO2 at 371C. Cells were washed three
times with ice-cold phosphate-buffered saline and radioactivity
was measured on 1480 Automatic gamma counter Wizard3
(Perkin Elmer). Data were normalized to the total protein
concentration.
Isolation of membrane-associated proteins and western
blotting
Plasma membrane-associated proteins were isolated using a
Plasma Membrane Protein extraction kit (BioVision, AH
Diagnostics AB, Ska ¨rholmen, Sweden). A total of 5 10
8 cells
were used for the protein extraction, which was performed as
suggested by the manufacturer. For western blot analysis, 15mg
of plasma membrane-associated proteins were separated on
4–12% poly-acrylamid gels (Invitrogen) and western blotting
was performed as described.
15 Antibodies against Na
þK
þ-
ATPase (Abcam) for membrane-associated proteins and against
b-actin for the cytosolic fraction were used as loading controls.
Primers and real-time PCR
The following primers for monitoring GLUT1 RNA expression
by real-time (RT) PCR were used: GLUT1-R 50-AAGCGGCC-
CAGGATC-30 and GLUT1-F 50-CATCAATGCCCCCCA-30.
Primers for human b-actin R 50-GCGGATGTCCACGTC-30 and
F5 0-GCCCTGAGGCACTCT-30 were used as control. Brieﬂy,
2 10
6 RS4;11 cells were grown in 5ml medium in six-well
plates for 24h before treatment with 100nM Dex for 16 or 24h.
The cells were washed once with phosphate-buffered saline,
and then total RNA from each sample was extracted with
TRI Reagent from Ambion (Applied Biosystems, Europe BV,
Stockholm, Sweden, AM9738). Complementary DNA was
synthesized from 1mg total RNA with SuperScript II Reverse
Transcriptase from Invitrogen, SYBR GREEN PCR Master Mix
was used for real-time PCR and the 7500 Real-Time PCR system
from Applied Biosystems, Europe BV. Standard curves with
GLUT1 and b-actin primers were generated using a control
sample of complementary DNA from RS4;11 cells.
Statistical analysis
Student’s t-test (Microsoft Excel), Wilcoxon scores rank-sum
(Mann–Whitney) test, Fisher’s exact test and Pearson’s test were
used for statistical analysis. The parameters used for each of
these tests are described in the corresponding Figure Legends.
Results
Profound effects of Dex treatment on glucose
metabolism
To determine the effects of Dex on glucose metabolism in ALL
cells, we screened a Dex-sensitive cell line, RS4;11
(ref. 11)
treated with Dex for 16 and 24h for a number of metabolic
molecules using liquid chromatography and mass spectrometry.
A glucose analog, 2-deoxy-D-glucose, 2-DG, was used in
parallel to block glucose metabolism.
9 The major initial
pathway in glucose metabolism is glycolysis that generates
pyruvate. Molecules formed during the conversion of glucose to
pyruvate, such as glyceraldehyde 3-phosphate and phosphoe-
nolpyruvate, were signiﬁcantly decreased after both Dex and
2-DG treatment (Figure 1). In addition, pyruvate is converted to
lactate to maintain glycolysis at a high rate via the generation of
NAD
þ, a reaction essential for cancer cells. Both the amounts
of lactate and NAD
þ molecules were signiﬁcantly decreased
after both Dex and 2-DG treatments. In the cell, phosphorylated
glucose may also enter the pentose phosphate pathway that is
often upregulated in cancer cells. The pentose phosphate
pathway generates ribose-5-phosphate and NADPH to support
nucleic acid synthesis. There was no increase, but rather a
decrease at 24h of ribose-5 phosphate and a prominent
decrease in NADP
þ at both 16 and 24h (data not shown and
Figure 1).
Pyruvate is normally converted into acetyl-CoA to serve as a
substrate for the citric acid (Krebs) cycle. Citrate is an early, and
malate is a late metabolite of the cycle; both were decreased in
the Dex or 2-DG-treated RS4;11 cells at 24h of treatment,
indicative of inhibition of the mitochondrial energy metabolism
as well (Figure 1).
Most of these metabolites were also reduced upon both Dex
and 2-DG treatment of another ALL cell line, CCRF-CEM, that is
moderately sensitive to 1mM of Dex
11 (data not shown). These
data show that Dex inhibits glucose metabolism, similar
to 2-DG.
Dex inhibits glucose consumption, utilization and
uptake
Similar to glucose, 2-DG is taken up by GLUTs, and is
phosphorylated by hexokinase to 2-deoxyglucose-6-phosphate,
but cannot be metabolized further. Data from the metabolic
screen made in the two different cell lines mentioned above
showed that Dex affects glucose metabolism in a manner similar
Glucocorticoids inhibit glucose metabolism in leukemic cells
E Buentke et al
3
Blood Cancer Journalto 2-DG. Therefore, we next asked whether Dex affects glucose
consumption from the growth medium. ALL cell lines were
grown for 24h in the absence or presence of Dex and the levels
of glucose in the growth medium were assessed using the
Amplex Red Glucose assay. 2-DG was used to block glucose
metabolism in parallel. The basal glucose concentration in the
culture medium before the addition of the drugs was measured
in each experiment for each cell line. The values following the
treatment of each sample were then subtracted from these
baseline values to obtain an estimate of glucose uptake from the
growth medium. Thus, RS4;11, SupB15, CCRF-CEM and Reh
ALL cell lines cultured in the absence of drugs consumed
glucose, while glucose consumption in 2-DG-treated cultures
was inhibited (Figures 2a–d). Dex inhibited glucose consump-
tion in RS4;11 and SupB15 cell lines but not in Dex-resistant
Reh
18 cells (Figures 2a, b and d). Inhibition of glucose
consumption was signiﬁcant in CCRF-CEM when 1mM and
100mM concentrations of Dex were used (Figure 2c). To
examine whether Dex affects glycolytic ﬂux, glucose utilization
in cells cultured in medium containing tritiated glucose was
assessed by measuring intracellular amounts of tritiated water.
16
Dex inhibited glucose utilization in RS4;11, and to a lesser
extent, in CCRF-CEM cells. Dex did not affect glucose utilization
in Reh cells at either 12 or 24h (Figure 2e). To further
understand the mechanism of inhibition of glucose utilization
by Dex treatment, we studied glucose uptake using tritium-
labeled 2-DG. Similar to glucose utilization, 2-DG uptake was
reduced in both RS4;11 and to a lesser extent in CCRF-CEM
cells and was unaffected in Reh cells (Figure 2f). Similarly,
[2–
18F] 2-ﬂuoro-2-deoxy-D-glucose, FDG uptake was inhibited
in both RS4;11 and SupB15 already after 6h of treatment
(Figure 2g). FDG uptake was also inhibited in CCRF-CEM
treated with 1 and 10mM of Dex, but was unaffected in Reh cells
(data not shown). Thus, the three different methods showed that
Dex inhibits glucose consumption, utilization and uptake in
RS4;11, SupB15 and CCRF-CEM but not in Reh ALL cell lines.
These data also suggested that inhibition of glucose uptake at as
early as 6h after Dex treatment, that is, before any apoptosis or
growth arrest would occur,
11 might represent the mechanism of
Dex-induced cell death in these cells.
Dex-induced cell death correlates with the inhibition of
glucose uptake
The ALL cell lines RS4;11 and SupB15 are sensitive to 100nM of
Dex and undergo extensive cell death after 36h of Dex
treatment while Reh cells are entirely resistant to Dex
(Figure 3a and Laane E et al.
18 The Dex antagonist RU486
inhibited this response in the sensitive lines, demonstrating the
speciﬁcity to Dex-induced effects. Thus, inhibition of glucose
metabolism and uptake by Dex in RS4;11 and Sup-B15 vs Reh
cell lines correlated with the ability of Dex to induce cell death.
CCRF-CEM cells start undergoing apoptosis with 10-fold higher
concentrations of Dex are used,
11 that is, with 1 and 10mM
(Figure 3b). Thus, even in these less-sensitive cells, inhibition of
glucose uptake correlated with cell death induced by higher
concentrations of the drug.
Figure 1 Profound inhibition of glucose metabolism by Dex treatment of RS4;11 cells. RS4;11 cells were left untreated (ctrl) or were treated with
100nM Dex or 2mM 2-DG for 16 and 24h in triplicates; one control was harvested at 24h. Metabolites were assessed by liquid chromatography
and mass spectrometry. The data were normalized to the standard and to the total area of metabolites under the curve and the mean values are
presented. Student’s t-test P values for the control vs Dex treatment at 16 or 24 h: glyceraldehyde 3-phosphate, Po0.01; phosphoenolpyruvate,
Po0.01; lactate, Po0.05; NAD, Po0.03; NADP, Po0.04; citrate and malate, Po0.05 only at 24h. All calculations, standard deviations and the
Student’s t-test (two-tailed, two-sample unequal variance) were made in Excel.
Glucocorticoids inhibit glucose metabolism in leukemic cells
E Buentke et al
4
Blood Cancer JournalTo further study whether inhibition of glucose uptake is
associated with cell death induced by Dex, we analyzed ALL
blasts derived from 19 patients with pediatric B-precursor ALL
isolated from bone marrow before clinical treatment. FDG
uptake and apoptosis were analyzed after 16 and 24h of Dex
treatment, respectively, similarly to the cell lines as described
above. The basal level of FDG uptake by the primary ALL cells
and the level of inhibition of FDG uptake following Dex
treatment varied largely between samples. Notably, the level of
cell death induced by Dex treatment ex vivo also varied
between samples. Figures 3c and d show representative data for
six samples: three that are Dex sensitive and threeFDex
resistant (Figure 3d). In four of them FDG uptake was inhibited,
while in two it was unaffected (Figure 3c). To further analyze the
data, we divided the 19 samples into two groups: one, in which
cell death was induced 1.2 fold or more as compared to their
respective controls (10 samples), and another, in which 24h of
Dex treatment did not induce any cell death (9 samples), and
studied the correlation to the inhibition of FDG uptake. FDG
uptake was inhibited in 90% of the ﬁrst group, that is, samples
that underwent apoptosis on Dex treatment. In contrast, FDG
uptake was inhibited only in 30% of the samples that were
insensitive to Dex-induced cell death (Figure 3e). The correla-
tion between cell death and inhibition of FDG uptake was thus
signiﬁcant according to the Fischer’s exact test (P¼0.019).
Furthermore, in order to test the association between changes in
FDG uptake and cell death in a fully unbiased manner, the level
of cell death compared with the level of inhibition of FDG
uptake was analyzed by regression analysis and by the Pearson’s
test. The results demonstrated that inhibition of glucose uptake
in primary ALL cells correlated with Dex-induced cell death and
might therefore represent a mechanism underlying Dex-induced
cell death (Figure 3f, R¼ 0.7).
To study whether inhibition of glycolysis contributed to the
Dex-induced cell death, we used dimethylsuccinate that can
feed into the Krebs cycle and thus by-pass glycolysis.
Dimethylsuccinate could partly, by around 40%, rescue
RS4;11 cells from Dex-induced cell death (Figures 3g and h,
P¼0.04). These data provided further evidence that inhibition
of glucose metabolism by Dex contributes to the pro-apoptotic
effects of this drug in ALL cells.
Dex inhibits GLUT1 expression
One of the cellular alterations in transformed cells is an
increased rate of glucose uptake that is associated with
increased expression of glucose transporters (GLUTs). GLUT1
belongs to the class 1 glucose transporters. It has a high afﬁnity
to glucose and has been shown to be expressed at high levels at
the membrane of tumor cells, including tumors of lymphoid
origin and ALL in particular.
2,3 PI3K signaling and AKT proteins
were shown to be essential for the transport of GLUT1 to the cell
surface in response to growth factors.
19 We previously found
that 16 and 24h of Dex treatment of RS4;11 cells led to the
inhibition of AKT phosphorylation.
18 We therefore tested
whether Dex would affect GLUT1 transmembrane expression
Figure 2 Inhibition of glucose consumption, utilization and uptake by Dex treatment of ALL cell lines. (a–d) RS4;11, SupB15, CCRF-CEM and Reh
ALL cell lines were cultured for 24h in the absence (ctrl) or presence of 100nM Dex (or indicated concentrations for CCRF-CEM cells) or 2-DG.
Glucose concentration in the medium was measured using the Amplex Red Glucose assay kit. The bars represent glucose consumption calculated
by subtracting the values from the baseline glucose concentration in the growth medium measured before the addition of the drugs. Experiments
were performed three independent times. Error-bars represent standard deviation. (e) RS4;11, CCRF-CEM and Reh cells were cultured in the
absence or presence of Dex (100nM for RS4 and Reh, 100mM for CEM cells) for 12 or 24h and incubated for an additional 90min with [
3H]-
glucose at 371C. Glucose utilization was studied by measuring resulting [
3H]-H2O. The data are a summary of three independent experiments and
presented as a ratio to control. (f) Cells were treated as in e. Glucose uptake was measured after 10min incubation at 371C with [
3H]-2-DG. The
data represent averages of three independent experiments and are presented as a ratio to control. (g) RS4;11 and SupB15 were cultured as in a in
triplicate and treated with 100nM Dex for 6h or 16h and glucose uptake was measured using FDG.
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treated with Dex for 24h and immunoblotting of plasma-
membrane-associated proteins after 16 and 24h of Dex
treatment demonstrated a decrease in GLUT1 expression
(Figures 4a and b). This was not observed in Reh cells
(Figure 4c). Thus, Dex treatment inhibited the levels of
membrane-associated GLUT1 in the sensitive but not in the
resistant ALL cell line. GLUT1 expression in cancer cells is also
regulated at the level of transcription.
2 Indeed, the GLUT1
mRNA levels dropped signiﬁcantly after 8, 16 and 24h of Dex
treatment, as monitored by real-time PCR (Figure 4d). Thus, Dex
inhibits GLUT1 expression and the availability of GLUT1 at the
plasma membrane in ALL cells, providing a plausible mechan-
ism for the inhibition of glucose uptake by GCs.
Increased cell death induced by Dex in low glucose
concentrations
Our results strongly suggested that inhibition of glucose uptake
by Dex leads to the death of ALL cells. It has been shown that
2-DG and prednisolone (or Dex) synergistically inhibit the
viability of GC-resistant ALL cell lines, whereas this synergism
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9 These data
together prompted us to investigate whether the lower glucose
levels available to the cells would augment Dex-induced cell
death. Dex-sensitive RS4;11 cells were cultured for 1–6 weeks in
medium containing twofold or fourfold lower levels of glucose as
compared with the normal cell culture medium. Cells grown in
1g/l or 0.5g/l of glucose showed no increase in basal apoptosis
(Figure 5a). Dex treatment led to a signiﬁcantly higher cell-death
rate in the cultures grown in lower glucose (Figure 5a; Po0.001
for either condition). We also asked whether the lower glucose
concentration would affect the basal and the Dex-modulated
glucose uptake. Culturing cells in the lower glucose concentra-
tions did not signiﬁcantly change the basal levels of glucose
uptake. However, under these conditions, the inhibition of
glucose uptake by Dex treatment was more pronounced than
under standard cell culture conditions (Figure 5b, Po0.03 for
either condition). Thus Dex treatment both inhibits glucose uptake
and kills ALL cells more efﬁciently under low glucose conditions.
Figure 4 Inhibition of GLUT expression by Dex. (a) RS4;11 cells were
cultured for 24h in the absence or presence of Dex. Expression of the
glucose transporter GLUT1 was assessed using immunostaining of living
cells and analysis by ﬂow cytometry. The bar chart represents the mean
ﬂuorescence intensity, MFI, with subtracted background staining. (b)R S 4 ; 1 1
cells were either left untreated or were treated with 100nM of Dex for 8, 16
and 24h and plasma-membrane-associated proteins were extracted as
described in materials and methods section. Protein samples (15mg/sample)
w e r es e p a r a t e do n4 – 1 2 %P A Ga n dw e s t e r nb l o tw a sp e r f o r m e dw i t ha n t i -
GLUT1 antibodies. A shorter (upper panel) and a longer (middle panel)
exposure of the same membrane are presented for clarity. Antibodies
against Na
þK
þ-ATPase (lower panel) were used as control for loading. The
chart below western ﬁgure represents quantiﬁcation of the GLUT1 signals as
a ratio to ATPase using Aida Image Analyzer, V.4.08. (c) Reh cells were
cultured, treated for 24h and processed as in B, except for 1mM of Dex was
used. (d) RS4;11 cells were cultured as in b; RNA was extracted and mRNA
expression of GLUT1 was analyzed by RT-PCR as described in materials
and methods section. A representative sample from three independent
experiments is shown. The data represent GLUT1 mRNA relative to the
b-actin expression levels, in relation to control.
Figure 5 Modulation of glucose uptake and cell death induced by
Dex in low glucose. (a, b) RS4;11 cells were grown in the indicated
glucose concentrations over a period of 7–40 days. Cells were either
left untreated or were treated with 100nM of Dex for 36 h. Apoptosis
was monitored by AnnexinV/PI stainings (a) and glucose uptake was
measured using FDG (b) as in Figure 2g.
Figure 3 Inhibition of glucose uptake correlates with the ability of Dex to induce cell death in ALL cells. (a) RS4;11, SupB15 and Reh cells were
cultured in the absence or presence of 100nM Dex for 36h and apoptosis was assessed by ﬂow cytometry as accumulation of Annexin V-positive/
TMRE-negative cells. To show the speciﬁcity of the response, the GC receptor inhibitor RU486 was added to the cells 1h before the addition of
Dex. (b) CCRF-CEM cells were cultured in the presence or absence of increasing concentrations of Dex for 48h and apoptosis was assessed by
annexin V staining and ﬂow cytometry. The data represent average of three independent experiments. (c) Leukemic cells from ALL patients were
cultured ex vivo in the presence or absence of 200nM Dex for 16h and FDG uptake was measured as in Figure 2g. (d) Leukemic cells from ALL
patients were cultured as in c, but for 24h and apoptosis was assessed by annexin V staining and ﬂow cytometry. The graph represents a ratio of
annexin V-positive cells relative to control. (e) Correlation between the inhibition of FDG uptake and cell death ex vivo induced by Dex. Primary
leukemic cells from 19 ALL samples were cultured, treated and analysed as in c and d. The samples were grouped according to sensitivity to Dex-
induced cell death, as follows: ‘die’Fsamples that show greater than 1.2 fold increase in AnnexinV-positive cells as compared with untreated
controls; ‘do not die’Fsamples show no increase in AnnexinV-positive as compared with untreated controls. The P¼0.019 was calculated using
the Fischer exact test and two-sided distribution. (f) The data from the experiments described in c–e were analyzed by regression analysis of the
correlation between the level of the inhibition of FDG uptake and the extent of cell death induced by Dex in the primary ALL cells from 18
individual patients ex vivo. One of the primary samples was omitted from this analysis due to outlying values. R¼ 0.7; P¼0.02. (g, h) DMS
overcomes Dex-induced apoptosis. RS4;11 cells were cultured in the absence or presence of 7.7mM DMS, treated with 100nM of Dex for 36h,
stained with AnnexinV and analyzed by ﬂow cytometry. The bar chart (h) represents average of three independent experiments; P¼0.04 was
calculated using the Wilcoxon rank-sum test for one-sided distribution.
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In this study, we demonstrated that the GC Dex had profound
effects on glucose metabolism in ALL cells. Dex was found to
inhibit glucose consumption, utilization and uptake leading to a
strong inhibition of glycolysis in ALL cell lines and primary ALL
blasts cultured ex vivo. GC hormones are normally secreted by
the adrenal gland and their effects in multiple tissues have
essential physiological roles in glucose, lipid and protein
metabolism and contribute to energy homeostasis. Excess
plasma levels of GCs may increase endogenous glucose
production both directly and indirectly, by antagonizing
insulin’s metabolic functions. GCs interfere with glucose uptake
by skeletal muscle tissue, which is responsible for 80% of
glucose uptake from the circulation. This occurs through
interference with the insulin-stimulated transport of GLUT4 to
the cell surface.
20 Previous studies have not investigated
whether GCs affect the glucose uptake/metabolism in
lymphoid/leukemic cells. We show in this study that, similarly
to the skeletal muscle tissue, Dex reduced the cell surface
GLUT1 expression in ALL cells, thus providing a plausible
mechanism for the subsequent dramatic effects of Dex on
glucose uptake and glycolysis in these cells.
As ALL cells, similar to tumor cells of other origin,
have increased glucose uptake and glucose dependence,
3 it
was logical to hypothesize that inhibition of glucose
uptake would lead to cell death. It was indeed a plausible
suggestion as inhibition of FDG uptake was signiﬁcant already at
6h after Dex treatment, well before the ﬁrst signs of apoptosis or
of the growth arrest occurred (data not shown). To test this
hypothesis, we used both ALL cell lines and primary ALL cells
from patients, and measured both the glucose uptake and
apoptotic effects induced by the drug. In the cell lines and, most
importantly, in the primary ALL cells, inhibition of glucose
uptake by Dex correlated with the ability of the drug to kill
the cells. Furthermore, Dex-induced cell death was attenuated
using dimethylsuccinate that allowed circumvention of glyco-
lysis and directly supported the Krebs cycle, providing more
evidence that the inhibition of glycolysis leads to cell death.
Interestingly, culturing an ALL cell line in a low glucose
medium or with addition of 2-DG slowed down or inhibited
growth but did not induce cell death per se as compared with
Dex treatment. This suggested that inhibition of glucose
metabolism is not the sole pro-apoptotic signal induced by
Dex. In fact, the combination of low glucose in the culture
medium and Dex had an additive effect on cell death in RS4;11
cells. Increased cell death also correlated with a more
pronounced inhibition of FDG uptake at half the standard
glucose concentration. It was found earlier that 2-DG and
prednisolone (or Dex) synergistically inhibit the viability of GC-
resistant ALL cell lines.
9 Thus, clearly, inhibition of glucose
uptake/metabolism contributes to the GC-induced cell death.
On the other hand, our data also suggest that GC-mediated
inhibition of glucose uptake is only part of the mechanisms
underlying GC-mediated cell death. Our data thus provide
evidence that modulating glucose levels in blood might change
the effectiveness of GC treatment in ALL.
It was demonstrated that GC resistance in precursor-B ALL is
associated with an increased expression of genes involved in
glucose metabolism
8 and that an increased glycolytic rate in
ALL cells is directly related to GC resistance.
9 In light of our
present data, one could speculate that the mechanism(s) of the
downregulation of GLUT1 by Dex are impaired in the resistant
cells, thus contributing to the resistance to the drug. Importantly,
this resistance could be reversed by drugs that inhibit glycolysis,
demonstrating that targeting the glycolytic pathway may be a
valuable strategy for modulating GC resistance.
9
Recently, it was demonstrated that an alternative mode of cell
death, autophagy, is involved in the response to anti-cancer
drugs and that the role of autophagy seems to be cell type and
drug speciﬁc in that it can either lead to cell survival or to cell
death.
21 We have recently shown that Dex induced a strong
autophagic response upstream of apoptosis in ALL and CLL
cells, and that this was a necessary step for the execution of cell
death.
18 We tested whether low glucose or 2-DG exposure
would induce autophagy and thus mimic the effect of Dex and
potentiate the effects of GCs. However, none of these agents
alone induced lipidation and cleavage of LC3 protein, the best
marker for autophagy available at present (data not shown).
More studies are thus required to analyze the effects of GLUT1
downregulation and glucose starvation on the autophagic
response in these cells and to reveal the role of this response
in GC-induced cell death of ALL cells.
In conclusion, our study links the inhibitory effects of GCs on
glucose uptake to GC-induced cell death, further revealing the
mechanisms of the pro-apoptotic action of these drugs in ALL.
A detailed understanding of the pro-apoptotic mechanisms will
facilitate the design of novel strategies to combat the survival of
malignant cells and to overcome resistance to GC treatment.
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